WVE
Price
$7.15
Change
+$0.13 (+1.85%)
Updated
Oct 3 closing price
Capitalization
1.12B
33 days until earnings call
XENE
Price
$39.61
Change
+$0.41 (+1.05%)
Updated
Oct 3 closing price
Capitalization
3.02B
32 days until earnings call
Interact to see
Advertisement

WVE vs XENE

Header iconWVE vs XENE Comparison
Open Charts WVE vs XENEBanner chart's image
Wave Life Sciences
Price$7.15
Change+$0.13 (+1.85%)
Volume$1.82M
Capitalization1.12B
Xenon Pharmaceuticals
Price$39.61
Change+$0.41 (+1.05%)
Volume$537.27K
Capitalization3.02B
WVE vs XENE Comparison Chart in %
WVE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
WVE vs. XENE commentary
Oct 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is WVE is a Hold and XENE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 05, 2025
Stock price -- (WVE: $7.15 vs. XENE: $39.61)
Brand notoriety: WVE and XENE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: WVE: 93% vs. XENE: 64%
Market capitalization -- WVE: $1.12B vs. XENE: $3.02B
WVE [@Biotechnology] is valued at $1.12B. XENE’s [@Biotechnology] market capitalization is $3.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $104.83B to $0. The average market capitalization across the [@Biotechnology] industry is $2.03B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

WVE’s FA Score shows that 0 FA rating(s) are green whileXENE’s FA Score has 1 green FA rating(s).

  • WVE’s FA Score: 0 green, 5 red.
  • XENE’s FA Score: 1 green, 4 red.
According to our system of comparison, XENE is a better buy in the long-term than WVE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

WVE’s TA Score shows that 5 TA indicator(s) are bullish while XENE’s TA Score has 5 bullish TA indicator(s).

  • WVE’s TA Score: 5 bullish, 5 bearish.
  • XENE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, XENE is a better buy in the short-term than WVE.

Price Growth

WVE (@Biotechnology) experienced а +5.15% price change this week, while XENE (@Biotechnology) price change was +4.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.93%. For the same industry, the average monthly price growth was +13.10%, and the average quarterly price growth was +80.18%.

Reported Earning Dates

WVE is expected to report earnings on Nov 06, 2025.

XENE is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+4.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XENE($3.02B) has a higher market cap than WVE($1.12B). XENE YTD gains are higher at: 1.046 vs. WVE (-42.199). WVE has higher annual earnings (EBITDA): -134.84M vs. XENE (-315.5M). XENE has more cash in the bank: 488M vs. WVE (208M). XENE has less debt than WVE: XENE (8.72M) vs WVE (21.7M). WVE has higher revenues than XENE: WVE (93.9M) vs XENE (7.5M).
WVEXENEWVE / XENE
Capitalization1.12B3.02B37%
EBITDA-134.84M-315.5M43%
Gain YTD-42.1991.046-4,035%
P/E RatioN/AN/A-
Revenue93.9M7.5M1,252%
Total Cash208M488M43%
Total Debt21.7M8.72M249%
FUNDAMENTALS RATINGS
WVE vs XENE: Fundamental Ratings
WVE
XENE
OUTLOOK RATING
1..100
637
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
74
Overvalued
PROFIT vs RISK RATING
1..100
10036
SMR RATING
1..100
9997
PRICE GROWTH RATING
1..100
6449
P/E GROWTH RATING
1..100
1006
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

WVE's Valuation (53) in the Biotechnology industry is in the same range as XENE (74). This means that WVE’s stock grew similarly to XENE’s over the last 12 months.

XENE's Profit vs Risk Rating (36) in the Biotechnology industry is somewhat better than the same rating for WVE (100). This means that XENE’s stock grew somewhat faster than WVE’s over the last 12 months.

XENE's SMR Rating (97) in the Biotechnology industry is in the same range as WVE (99). This means that XENE’s stock grew similarly to WVE’s over the last 12 months.

XENE's Price Growth Rating (49) in the Biotechnology industry is in the same range as WVE (64). This means that XENE’s stock grew similarly to WVE’s over the last 12 months.

XENE's P/E Growth Rating (6) in the Biotechnology industry is significantly better than the same rating for WVE (100). This means that XENE’s stock grew significantly faster than WVE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
WVEXENE
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
73%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 5 days ago
76%
Bullish Trend 2 days ago
72%
Declines
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 10 days ago
71%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
WVE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XENE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ARTRX36.070.13
+0.36%
Artisan Global Opportunities Inv
HDVVX15.58N/A
N/A
Hartford International Equity R6
FDVLX14.58N/A
N/A
Fidelity Value
MASGX14.42N/A
N/A
Matthews Emerging Markets Sust Fut Inv
AALIX13.14N/A
N/A
Cavanal Hill Hedged Equity Income A

WVE and

Correlation & Price change

A.I.dvisor indicates that over the last year, WVE has been closely correlated with PRQR. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if WVE jumps, then PRQR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To WVE
1D Price
Change %
WVE100%
+1.85%
PRQR - WVE
67%
Closely correlated
+8.89%
OCUL - WVE
51%
Loosely correlated
+3.16%
KRRO - WVE
50%
Loosely correlated
+1.09%
ETHZ - WVE
44%
Loosely correlated
-1.94%
XENE - WVE
44%
Loosely correlated
+1.05%
More